Empagliflozin and semaglutide combination improves glycemic control and BP but not arterial stiffness
A recent 32-week study investigated the effects of empagliflozin, semaglutide, and their combination on vascular function. This study published in the Diabetes, Obesity and Metabolism revealed unexpected results that could reshape the strategies of diabetes management.
The involved a total of 120 patients with type 2 diabetes and these participants were divided into four groups: placebo, semaglutide, empagliflozin, and a combination of both medications. The co-primary outcomes of this study were changes in arterial stiffness and kidney oxygenation, with a specific focus on carotid-femoral pulse wave velocity as a measure of arterial stiffness.
The carotid-femoral pulse wave velocity remained unchanged across all the groups, including the combination treatment which challenges the previous assumptions about the efficacy of these medications on arterial stiffness.
The study uncovered that the combination treatment group experienced a significant 10 mmHg reduction in 24-hour systolic blood pressure, outperforming both the placebo and monotherapy groups. This reduction is considered clinically important and suggests a potential avenue for managing cardiovascular risk in individuals with type 2 diabetes.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.